{"id":"imeglimin","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"A10BX15","category":"atc"},{"label":"Active","category":"status"},{"label":"Diabetes mellitus type 2","category":"indication"},{"label":"SUMITOMO DAINIPPON PHARMA Co., Ltd.","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"SUMITOMO DAINIPPON PHARMA Co., Ltd.","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=IMEGLIMIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:17:19.222487+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:17:25.994629+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IMEGLIMIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:17:26.666484+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297514/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:17:27.106681+00:00"}},"allNames":"twymeeg","offLabel":[],"synonyms":["imeglimin","imeglimin hydrochloride","twymeeg"],"timeline":[{"date":"2021-06-23","type":"positive","source":"DrugCentral","milestone":"PMDA approval (SUMITOMO DAINIPPON PHARMA Co., Ltd.)"}],"approvals":[{"date":"2021-06-23","orphan":false,"company":"SUMITOMO DAINIPPON PHARMA Co., Ltd.","regulator":"PMDA"}],"brandName":"Twymeeg","ecosystem":[{"indication":"Diabetes mellitus type 2","otherDrugs":[{"name":"acarbose","slug":"acarbose","company":"Bayer Hlthcare"},{"name":"acetohexamide","slug":"acetohexamide","company":"Lilly"},{"name":"albiglutide","slug":"albiglutide","company":"Glaxosmithkline Llc"},{"name":"alogliptin","slug":"alogliptin","company":"Takeda Pharms Usa"}],"globalPrevalence":537000000}],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"IMEGLIMIN is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which means it blocks the action of the DPP-4 enzyme that breaks down incretin hormones. This leads to increased levels of incretin hormones, which in turn stimulate the release of insulin and decrease glucagon levels, ultimately lowering blood glucose levels."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5483","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=IMEGLIMIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IMEGLIMIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:01:25.626183","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:17:29.091632+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"repaglinide","drugSlug":"repaglinide","fdaApproval":"1997-12-22","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nateglinide","drugSlug":"nateglinide","fdaApproval":"2000-12-22","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"pramlintide","drugSlug":"pramlintide","fdaApproval":"2005-03-16","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"tirzepatide","drugSlug":"tirzepatide","fdaApproval":"2022-05-13","patentExpiry":"Jun 14, 2039","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"imeglimin","indications":{"approved":[{"name":"Diabetes mellitus type 2","source":"DrugCentral","snomedId":44054006,"regulator":"FDA","usPrevalence":37300000,"globalPrevalence":537000000,"prevalenceMethod":"curated","prevalenceSource":"IDF Diabetes Atlas, 2024"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"repaglinide","brandName":"repaglinide","genericName":"repaglinide","approvalYear":"1997","relationship":"same-class"},{"drugId":"nateglinide","brandName":"nateglinide","genericName":"nateglinide","approvalYear":"2000","relationship":"same-class"},{"drugId":"pramlintide","brandName":"pramlintide","genericName":"pramlintide","approvalYear":"2005","relationship":"same-class"},{"drugId":"tirzepatide","brandName":"tirzepatide","genericName":"tirzepatide","approvalYear":"2022","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07436182","phase":"PHASE4","title":"Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2026-03-01","conditions":["Mitochondria","Metformin"],"enrollment":176,"completionDate":"2026-06-01"},{"nctId":"NCT07127094","phase":"PHASE1","title":"Bioequivalence Assessment Between Two Imeglimin Hydrochloride Film Coated Tablet Formulations","status":"COMPLETED","sponsor":"Aya Mohammed Abdel Magid Abdel Hamid","startDate":"2025-03-09","conditions":["Bioequivalence Study in Healthy Subjects"],"enrollment":29,"completionDate":"2025-06-18"},{"nctId":"NCT05366868","phase":"PHASE4","title":"Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"National Center for Global Health and Medicine, Japan","startDate":"2022-05-26","conditions":["Diabetes Mellitus, Type 2"],"enrollment":567,"completionDate":"2027-03-31"},{"nctId":"NCT03802786","phase":"PHASE1","title":"Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects","status":"COMPLETED","sponsor":"Poxel SA","startDate":"2018-11-06","conditions":["Hepatic Impairment"],"enrollment":14,"completionDate":"2019-07-08"},{"nctId":"NCT03646331","phase":"PHASE1","title":"Bioequivalence of Imeglimin Tablet Formulations","status":"COMPLETED","sponsor":"Poxel SA","startDate":"2018-09-03","conditions":["Bioequivalence"],"enrollment":16,"completionDate":"2018-10-02"},{"nctId":"NCT03618316","phase":"PHASE1","title":"Effect of Cimetidine on the PK of Imeglimin","status":"COMPLETED","sponsor":"Poxel SA","startDate":"2018-06-19","conditions":["Healthy"],"enrollment":16,"completionDate":"2018-07-27"},{"nctId":"NCT02924337","phase":"PHASE1","title":"Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects","status":"COMPLETED","sponsor":"Poxel SA","startDate":"2016-09","conditions":["Qt Interval, Variation in"],"enrollment":55,"completionDate":"2016-12"},{"nctId":"NCT02373150","phase":"PHASE1","title":"Safety, Tolerability and PK of Imeglimin in Japanese Volunteers","status":"COMPLETED","sponsor":"Poxel SA","startDate":"2015-02","conditions":["Type 2 Diabetes Mellitus"],"enrollment":48,"completionDate":"2015-10"},{"nctId":"NCT01951235","phase":"PHASE2","title":"A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Poxel SA","startDate":"2013-01","conditions":["Type 2 Diabetes Mellitus"],"enrollment":315,"completionDate":"2014-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"UU226QGU97","INN_ID":"8969","UMLSCUI":"C3501765","chemblId":"CHEMBL4297514","ChEMBL_ID":"CHEMBL4297514","KEGG_DRUG":"D11807","DRUGBANK_ID":"DB12509","PUBCHEM_CID":"24812808","SECONDARY_CAS_RN":"2650481-44-8","MESH_SUPPLEMENTAL_RECORD_UI":"C575881"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"SUMITOMO DAINIPPON PHARMA Co., Ltd.","relationship":"Current Owner"}],"publicationCount":182,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A10BX15","allCodes":["A10BX15"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"SUMITOMO DAINIPPON PHARMA Co., Ltd.","companyId":"sumitomo-dainippon-pharma-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2021-06-23T00:00:00.000Z","mah":"SUMITOMO DAINIPPON PHARMA Co., Ltd.","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Twymeeg","application_number":"Twymeeg"}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:17:29.091632+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}